Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $23.6 million.

  • Caribou Biosciences' Accumulated Expenses fell 23.96% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 23.96%. This contributed to the annual value of $23.6 million for FY2024, which is 11.76% up from last year.
  • Per Caribou Biosciences' latest filing, its Accumulated Expenses stood at $23.6 million for FY2024, which was up 11.76% from $21.1 million recorded in FY2023.
  • In the past 5 years, Caribou Biosciences' Accumulated Expenses registered a high of $23.6 million during FY2024, and its lowest value of $9.0 million during FY2020.
  • In the last 3 years, Caribou Biosciences' Accumulated Expenses had a median value of $21.1 million in 2023 and averaged $20.3 million.
  • Data for Caribou Biosciences' Accumulated Expenses shows a peak YoY spiked of 46.39% (in 2021) over the last 5 years.
  • Over the past 5 years, Caribou Biosciences' Accumulated Expenses (Yearly) stood at $9.0 million in 2020, then skyrocketed by 46.39% to $13.1 million in 2021, then grew by 22.40% to $16.1 million in 2022, then soared by 31.44% to $21.1 million in 2023, then increased by 11.76% to $23.6 million in 2024.